Tirzepatide 5mg
Size: 5mg | 99% Purity
M.Wt: 4813.48
Formula: C225H348N48O68
Solubility: H2O
Purity: >99%
Storage: -20°C / 3 years
Half life: Not established
CAS No.: 2023788-19-2
| Available sizes | 0.05kg |
|---|---|
| Purity (HPLC) | >99% |
| Molecular weight | 4813.48 g/mol |
| Molecular formula | C225H348N48O68 |
| CAS number | 2023788-19-2 |
| Synonyms | LY3298176, GIP/GLP-1 Dual Agonist, Mounjaro Active Compound |
| Solubility | H2O |
| Storage | -20°C / 3 years |
| Half-life | Not established |
Peptide sequence
Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2HPLC and MS verified by UKAS-accredited laboratories.
Royal Mail 24 and DPD Next Day options.
COA and batch number on every vial.
Description
Size: 5mg | 99% Purity
M.Wt: 4813.48
Formula: C225H348N48O68
Solubility: H2O
Purity: >99%
Storage: -20°C / 3 years
Half life: Not established
CAS No.: 2023788-19-2
*(This is a lyophilised powder and will need reconstitution — Sterile Water for reconstitution is supplied separately.)
Reconstitution
For peptides supplied as lyophilised powder, reconstitute in bacteriostatic water or sterile saline at the concentration appropriate to your protocol. Allow the vial to come to room temperature before opening, add solvent slowly down the inside wall (do not directly onto the powder), and gently invert until clear. Do not vortex.
Reconstituted solutions are typically stable at 2–8°C for the durations published in the corresponding peer-reviewed reference. For long-term storage, aliquot and freeze at −20°C; avoid repeated freeze–thaw cycles.
Research literature
Selected peer-reviewed publications from PubMed referencing this compound. Provided for research orientation — not an endorsement of any clinical application. Each citation links to the canonical PubMed record.
-
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
Coskun T et al. · Molecular metabolism · 2018
PubMed PMID 30473097 -
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
Aronne LJ et al. · JAMA · 2024
PubMed PMID 38078870 -
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Frias JP et al. · Lancet (London, England) · 2018
PubMed PMID 30293770
You may also need
Related compounds
